Video: Dr. Ribas on Triplet Regimens in Melanoma

Excerpt:

“Antoni Ribas, MD, PhD, professor of Hematology and Oncology and director of the Tumor Immunology Program Area at UCLA Jonsson Comprehensive Cancer Center, discusses triplet therapies for patients with melanoma and the sequencing challenges associated with the approvals of additional agents in the field.

“Though current immunotherapy regimens are showing significant activity in patients, Ribas says the response rate is not 100%; therefore, there needs to be investigations of other ways to modulate the immune system. Patients who benefit from PD-1 monotherapy should not receive any more, as it will lessen treatment-related toxicities, he adds.”

Watch the video.

Do you have questions about this story? Let us know in a comment below. If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to use our Ask Cancer Commons service.


Video: Dr. Matthew Cooperberg on Surgery for Aggressive Prostate Cancer

“Matthew Cooperberg, MD, genitourinary cancer specialist, University of California San Francisco, discusses the rise in aggressive management of men with high-risk prostate cancer. Cooperberg says the proportion of men who are receiving hormonal therapy alone had been rising consistently over the course of a 15 year period, up until 2010, to about 50%. Since then, Cooperberg says that number has dropped to about half of what it was, or 25%, which is attributed to more aggressive treatment.

“Cooperberg says local therapy for men with high-risk prostate cancer was normally radiotherapy, with surgery not being nearly as common. He adds that a growing body of evidence dictates that surgery in prostate cancer may be a more effective local therapy than radiation alone. According to the body of evidence, cancer-related survival and overall survival were normally boosted when surgery was involved for these patients.”

Click through to watch the video.


Video: Dr. Tara Gangadhar on Epacadostat/ Pembrolizumab Combination

“Tara C. Gangadhar, MD, Assistant Professor of Medicine at the Hospital of the University of Pennsylvania, discuses preliminary results from a phase I/11 study of epacadostat in combination with pembrolizumab.

“Epacadostat, an IDO inhibitor, and pembrolizumab, a PD-1 blockade, were tested in combination in patients with various advanced cancers to evaluate the safety of the drugs together.

“To date, 56 patients with advanced cancers have been treated with the combination, including 20 patients with melanoma.”

Click through to watch the video.


Video: Dr. Kari Wisinski on Palbociclib for Metastatic Breast Cancer

“Kari Wisinski, MD, medical oncologist with University Of Wisconsin Health and the University of Wisconsin Carbone Cancer Center, discusses the use of palbociclib for patients with ER-positive and HER2-negative breast cancer.

“Currently there is not a specific patient population that has been identified as ideal for palbociclib, says Wisinski.

“The PALOMA-3 trial demonstrated that palbociclib plus fulvestrant compared with fulvestrant plus placebo improved progression-free survival (PFS) in women with ER-positive and HER2-negative metastatic breast cancer following disease progression. Based on these results, the drug gained accelerated approval in February 2015.

“The PFS data is impressive, says Wisinski, and the swift approval of the drug has benefited patients who need to delay chemotherapy while maintaining PFS.”


VIDEO: 'Full Spectrum' of Melanoma Prevention, Treatment Options Available

“In this video, Sancy A Leachman, MD, PhD, discusses the latest developments in the prevention and treatment of melanoma the American Academy of Dermatology Annual Meeting.

“ ‘We finally have a full spectrum of prevention, early treatment and late treatment options for melanoma, which is the first time we’ve had this sort of spectrum of possibilities’ Leachman, professor and chair of the Department of Dermatology at Oregon Health and Science University and director of the melanoma program at Knight Cancer Institute, told Healio.com/Dermatology.

“Melanoma is becoming more like childhood leukemia, Leachman said, in that physicians are ‘whittling away at the number of people dying from the disease and simultaneously, in dermatology we have the opportunity to whittle away the number that ever get there.’

“Among new prevention and treatment options, Leachman discussed applying genetics for various testing and identifying which patients are likely to respond to certain diseases.”

Click through to see the video.


Video: Marty Tenenbaum Speaks at the ALCF's Lung Cancer Living Room Event

Earlier this year, Cancer Commons founder Marty Tenenbaum, PhD, spoke at the Bonnie J. Addario Lung Cancer Foundation’s (ALCF) monthly Lung Cancer Living Room event. Marty’s own cancer diagnosis and treatment journey inspired his current mission: to make sure critical information is shared and gets to the patients who need it. By collecting data from thousands of patient-donated lung cancer stories, Cancer Commons can begin to show patients and doctors patterns in treatment choices, side effects, quality of life, outcomes, and more.

The video from the event is now available:

Lung Cancer Living Room 04-22-14 from Peninsula TV on Vimeo.

The ALCF, one of our partner organizations, works directly with individual lung cancer patients to ensure they each receive the best possible care. The Lung Cancer Living Room is a monthly in-person and online support group event that informs patients about lung cancer.

Click here for more information, including how to attend in person (in San Carlos, CA) or online. Click here to read the description of Marty’s upcoming event.


Video: CC Board Member Dr. Larry Marton Discusses Personalized Medicine in New Podcast

In a recent video podcast, Cancer Commons board member Dr. Larry Marton discusses quality assurance in the context of personalized medicine. Dr. Marton is heavily involved at Cancer Commons; he tells our story at the 32:00 mark. From Mendelspod, makers of the podcast:

“Larry’s core message is that we must improve the quality of new clinical tests which have been translated from research. It is the key to demonstrating clinical relevance, he says. There are issues with sampling, with analytics, and with compliance. What can those in the industry do to better the quality assurance? And how can the industry better engage the medical community? A veteran shares his insights.”

You can also watch, listen, or download here.


Watch and Read: Dr. Tenenbaum on The Impact of Personalized Medicine

On May 7, Cancer Commons founder Marty Tenenbaum hosted a panel in The Scientists three-part webinar series Decoding DNA: New Twists and Turns. A summary of the webinar was featured in the June issue of The ScientistThe Scientist June 2013 JMT Webinar. Watch Dr. Tenenbaum and other experts discuss The Impact of Personalized Medicine:

The Impact of Personalized Medicine from thescientistllc on Vimeo:

“After the human genome was sequenced, Personalized Medicine became an end goal, driving both academia and the pharma/biotech industry to find and target cellular pathways and drug therapies that are unique to an individual patient. The final webinar in the series will help us better understand The Impact of Personalized Medicine, what we can expect to gain and where we stand to lose.

Panelists:

Jay M. (‘Marty’) Tenenbaum, Ph.D., Chairman and Founder, Cancer Commons

Amy P. Abernethy, M.D., Associate Professor of Medicine, Duke University School of Medicine and Director of the Duke Cancer Care Research Program

Geoffrey S. Ginsburg, MD, PhD, Director, Genomic Medicine, Duke Institute for Genome Sciences & Policy Executive Director, Center for Personalized Medicine Duke Medicine, Professor of Medicine and Pathology Duke University Medical Center

Abhijit ‘Ron’ Mazumder, Ph.D., Global Head, Research & Product Development, Janssen Diagnostics, Janssen Pharmaceutical companies of Johnson and Johnson”